Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea

Papulopustular Rosacea Clinical Trial

Official title:
An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily in Subjects With Moderate Papulopustular Rosacea

Status Completed

Clinical Trial Summary

Subjects with moderate papulopustular rosacea will be treated either with azelaic acid 15% gel topically plus an anti-inflammatory dose of doxycyline (40mg) daily or with metronidazole 1% gel topically once daily plus an anti-inflammatory dose of doxycycline (40mg) over at total of twelve weeks to determine the rapidity of improvement, and the length of time to reach 25%, 50% and 75% clearing compared to baseline.

Clinical Trial Description

The change in inflammatory lesion count will be assessed at each post-baseline visit by an analysis of variance model (ANOVA) with factors treatment and center, but not including treatment-by-center interaction.

Investigator's Global Assessment (IGA) of papulopustular rosacea (static score): 0 - Clear (Virtually no rosacea ie, no papules and/or pustules; no or residual erythema; no or mild to moderate degree of telangiectasia may be present); 1 - Minimal (Rare papules and/or pustules; residual to mild erythema; mild to moderate degree of telangiectasia may be present); 2 - Mild (Few papules and/or pustules; mild erythema; mild to moderate degree of telangiectasia may be present); 3 - Mild to moderate (Distinct number of papules and/or pustules; mild to moderate erythema; mild to moderate degree of telangiectasia may be present); 4 - Moderate (Pronounced number of papules and/or pustules; moderate erythema; mild to moderate degree of telangiectasia may be present); 5 - Moderate to severe (Many papules and/or pustules, occasionally with large inflamed lesions; moderate erythema; moderate degree of telangiectasia may be present); 6 - Severe (Numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate or severe erythema; moderate or severe degree of telangiectasia may be present). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00855595
Study type	Interventional
Source	LEO Pharma
Contact
Status	Completed
Phase	Phase 4
Start date	February 2009
Completion date	July 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03276936` - A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea	Phase 3
Completed	`NCT02601963` - Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea	Phase 2
Completed	`NCT02268474` - Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea	N/A
Completed	`NCT01555463` - Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea	Phase 3
Active, not recruiting	`NCT03667222` - Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea	Phase 2
Terminated	`NCT03564145` - A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea	Phase 3
Completed	`NCT05150587` - Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea	Phase 2
Completed	`NCT03263273` - Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea	Phase 2
Completed	`NCT05343455` - A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)	Phase 3
Completed	`NCT01872715` - Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea	Phase 4
Completed	`NCT01784133` - A Twelve Week Safety and Efficacy Study in Rosacea	Phase 2
Completed	`NCT05296629` - A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.	Phase 3
Completed	`NCT05838170` - Study of TP-04 in Participants With Papulopustular Rosacea	Phase 2
Recruiting	`NCT06013371` - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea	Phase 2
Recruiting	`NCT03864978` - Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test	Phase 2
Completed	`NCT03564119` - A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea	Phase 3
Completed	`NCT03079531` - Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea	Phase 1/Phase 2
Completed	`NCT01045551` - Open Label Pilot Study of Apremilast in Treatment of Rosacea	Phase 2
Completed	`NCT03448939` - A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea	Phase 3
Completed	`NCT05675501` - Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.